Paratek Pharmaceuticals, Inc. (PRTK) SEC Filing 8-K Material Event for the period ending Thursday, June 27, 2019

Paratek Pharmaceuticals, Inc.

CIK: 1516551 Ticker: PRTK

View differences made from one to another to evaluate Paratek Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Paratek Pharmaceuticals, Inc..


Assess how Paratek Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Paratek Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Paratek Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: PRTK
CIK: 1178711
Form Type: 8-K Corporate News
Accession Number: 0001564590-19-024440
Submitted to the SEC: Tue Jul 02 2019 5:22:45 PM EST
Accepted by the SEC: Tue Jul 02 2019
Period: Thursday, June 27, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation
  4. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: